PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
 
Neurobiol Aging. 2013 December; 34(12): 2890.e1–2890.e5.
PMCID: PMC3898264

A novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family[star]

Abstract

Triggering receptor expressed on myeloid cells 2 (TREM2) homozygous mutations cause Nasu-Hakola disease, an early-onset recessive form of dementia preceded by bone cysts and fractures. The same type of mutations has recently been shown to cause frontotemporal dementia (FTD) without the presence of any bone phenotype. Here, we further confirm the association of TREM2 mutations with FTD-like phenotypes by reporting the first compound heterozygous mutation in a Turkish family.

Keywords: TREM2, Nasu-Hakola, Frontotemporal dementia, Compound heterozygous

1. Introduction

Nasu-Hakola disease (NHD, OMIM 221770), also known as polycystic lipomembranous osteodysplasia with sclerosing leukoencephalopathy, is a rare autosomal recessive disease characterized by a combination of progressive young-onset dementia and multifocal bone cysts (Paloneva et al., 2001). In most Nasu-Hakola patients, the clinical course of the disease can be divided into 4 stages: (1) the latent stage with normal early development; (2) the osseous stage beginning at the third decade of life, characterized by pain and swelling in ankles and feet followed by frequent bone fractures; (3) the early neuropsychiatric stage occurring at the fourth decade of life, presenting with a frontal lobe syndrome including euphoria and social disinhibition; and (4) the late neuropsychiatric stage, characterized by profound dementia, loss of mobility, and death usually by age of 50 years (Klunemann et al., 2005). NHD is caused by mutations in 1 of 2 genes: TYRO protein tyrosine kinase–binding protein (TYROBP) on chromosome 19q13.1 and triggering receptor expressed on myeloid cells 2 (TREM2) on chromosome 6p21.1.

Recently, cases with homozygous mutations in TREM2 have been described to present atypical phenotypes resembling behavioral variant frontotemporal dementia (bvFTD) and lacking stage (2) of the clinical picture described previously (Chouery et al., 2008; Giraldo et al., 2013; Guerreiro et al., 2013b).

At present, 14 different mutations have been identified in TREM2 including nonsense, missense, small deletions, and splice site homozygous mutations (Giraldo et al., 2013). Here, we report the first TREM2 compound heterozygous mutation identified in a Turkish family presenting with an FTD-like phenotype.

2. Methods

2.1. Patients

The proband is currently being followed in the outpatient clinic of the Behavioral Neurology and Movement Disorders Unit, Istanbul Faculty of Medicine, Istanbul University. She was hospitalized in 2012 for a detailed neurologic workup. Written informed consent was obtained from all family members, and this study was approved by the ethical committee of the Istanbul University.

2.2. Genetic analysis

DNA was extracted from blood samples, according to standard procedures. For the proband, all coding exons of TREM2 were amplified by polymerase chain reaction (PCR) using Roche FastStart PCR Master Mix (Roche Diagnostics Corp). The PCR products were sequenced using the same forward and reverse primers (primers available on request) with Applied Biosystems BigDye terminator version 3.1 sequencing chemistry and run on an ABI3730XL genetic analyzer as per the manufacturer's instructions (Applied Biosystems). The sequences were analyzed using Sequencher software, version 4.2 (Gene Codes). For family members, only exon 2 of TREM2 was tested.

3. Results

3.1. Case report

The proband is a 41-year-old female who presented with a 1-year history of a change in personality. She had become increasingly apathetic, and her husband reported that she had become less empathic toward close family and friends, unexpectedly leaving her husband and their child in the United States to move back to her parents' house in Turkey. At this time, her mother noticed that she had started to become more perseverative in her behavior and developing a change in food preference, eating more junk food. She also started to have mild word-finding difficulties. She had been previously fit and well apart from having had 2 previous generalized tonic-clonic seizures (one 4 years earlier and one 2 years earlier).

Her parents were originally from the same city (Erzincan) with a population of about 225,000 inhabitants, located in the eastern part of Turkey and were both clinically healthy. She had 2 siblings, a brother who was well and a sister who had also developed progressive cognitive impairment and behavioral problems with generalized tonic-clonic seizures starting in her 30s (Fig. 1).

Fig. 1
Pedigree of the family where the compound heterozygous mutation p.[(Y38C)];[(D86V)] in TREM2 was found. The arrowhead indicates the proband. Black filled symbols represent affected subjects with dementia. White symbols represent unaffected family members. ...

She scored 44 on the Addenbrooke's cognitive examination (range 0–100, higher scores indicating better performance) and 28 on the frontal behavioral inventory (range 0–72, higher scores indicating worse behavioral symptoms; disinhibition subscore 11, negative behavior subscale score 17). Formal neuropsychometry testing revealed deficits in executive function, particularly abstract thinking, planning, and inhibition. There was also evidence of language dysfunction with nonfluent speech, anomia, and phonemic paraphasias although comprehension and repetition were normal. Other cognitive domains were relatively intact, and both neurologic and general systemic examinations were normal.

Blood tests were normal including serum calcium, phosphate, and parathyroid hormone. Cerebrospinal fluid analysis revealed a mild pleocytosis (10 lymphocytes per cubic millimeter) and mildly increased protein (54 mg/dL) with positive unmatched oligoclonal bands. Electroencephalography was normal. Magnetic resonance imaging of the brain showed atrophy mainly located in the frontal, lateral temporal, and parietal cortices and also the caudate nuclei with marked thinning of the corpus callosum and enlargement of the ventricular system. On T2 and fluid-attenuated inversion recovery imaging, there was evidence of diffuse hyperintensities in the periventricular, frontal, and occipitoparietal white matter (Fig. 2). There were also symmetrical hypointense lesions bilaterally in the globus pallidus on T1, T2, and fluid-attenuated inversion recovery imaging (Fig. 3). These were considered to be calcification because computed tomography of the brain revealed marked hyperdense lesions (Fig. 4) in the same areas. Further tests included a skeletal X-ray survey, which showed no bone cysts.

Fig. 2
Magnetic resonance imaging of the proband. (A) Transverse T1-weighted image shows atrophy of the frontoparietal cortices. (B) Transverse fluid-attenuated inversion recovery image demonstrates mild but diffuse hyperintense appearance of the white matter, ...
Fig. 3
Both T1 and fluid-attenuated inversion recovery images demonstrate symmetrical hypointense lesions in basal ganglia.
Fig. 4
Computed tomography of the proband reveals symmetrical hyperdense lesions resembling calcifications in the globus pallidus.

3.2. Genetic analysis

In the proband, PCR and direct sequencing analysis of the 5 exons and exon-intron boundaries of TREM2 identified 2 different missense heterozygous mutations: c.113A>G, p.Y38C and c.257A>T, p.D86V in exon 2 (NM_018965.3).

To determine if the patient was a compound heterozygote, we sequenced exon 2 in the parents. The father carried the p.Y38C heterozygous variant and the mother carried the p.D86V also heterozygous; thus, the proband carries a compound heterozygous mutation: c.[113A>G];[257A>T]; p.[(Y38C)];[(D86V)].

To assess segregation of the mutation with the disease, we sequenced 2 siblings, 1 affected and 1 unaffected. The compound heterozygous mutation segregated with the disease, being present in the affected siblings and absent in the unaffected, who carried only one of the variants (p.Y38C) (Fig. 1).

None of these variants are reported on large genetic databases (dbSNP version 137, 1000Genomes Project or Exome Variant Server, NHLBI GO Exome Sequencing Project, Seattle, WA, http://evs.gs.washington.edu/EVS/, accessed on May, 2013), but we have previously reported both changes in the Turkish population. Homozygosity for the p.Y38C mutation was found in the only affected subject from family 2, and p.D86V was found in heterozygosity in a healthy control individual from 76 Turkish controls screened for TREM2 exon 2 mutations in our previous study (Guerreiro et al., 2013b).

4. Discussion

Both homozygous and compound heterozygous mutations in TYROBP are known to cause NHD (Kuroda et al., 2007). Homozygous mutations in TREM2 also cause NHD. More recently, we and others have found homozygous mutations in this gene to be associated with bvFTD-like phenotype without any associated bone involvement (Chouery et al., 2008; Giraldo et al., 2013; Guerreiro et al., 2013b). Here, we report the first compound heterozygous mutation in TREM2, which was found to be associated with FTD phenotype in a Turkish family.

The proband in the family here described was identified because she presented a clinical picture similar to the 3 previous bvFTD-like cases with homozygous TREM2 mutations we reported before (Guerreiro et al., 2013b). In addition to these 3 Turkish cases, 2 other families were also reported to carry homozygous mutations in TREM2, presenting with a bvFTD-like phenotype without bone cysts. Chouery et al. (2008) described a Lebanese family presenting with a young-onset dementia without bone cysts where 3 affected subjects carried a deletion (c.40+3delAGG) in the 5′ consensus donor splice site in intron 1 of TREM2. These affected individuals developed personality and behavioral changes at the age of 30–35 years, culminating in severe dementia. Brain magnetic resonance imaging showed cortical atrophy with periventricular white matter disease (Chouery et al., 2008). More recently, Giraldo et al. (2013) reported a novel homozygous nonsense mutation (p.W198X) in a Colombian family with an autosomal recessive pattern of inheritance of FTD, also without bone cysts. These patients started to develop behavioral and personality changes around the age of 45–50 years. Similar to this case and the previously described Turkish cases, the affected siblings in the Colombian family also developed seizures (Table 1).

Table 1
Main features of all the patients described in the literature with TREM2 mutations presenting without an osseous phenotype

Dementia in the form of an early-onset personality change, resembling bvFTD, seems to be the most common feature of all these reported cases, most often associated with seizures and characteristic imaging findings, such as callosal atrophy and diffuse white matter lucency. Familial FTD accounts for >40% of all cases, and to date, several genetic causes of the phenotype have been described. However, all the 7 genes with mutations causing familial FTD (i.e., MAPT, GRN, C9ORF72, VCP, CHMP2B, TARDBP, and FUS) are dominantly inherited. TREM2 mutations appear to be the first addition to this list as a recessively inherited genetic cause. We suggest that a family history of consanguinity along with somewhat atypical features, such as seizures and callosal atrophy, in a patient presenting with a bvFTD phenotype should prompt the diagnostician to look for a likely TREM2 homozygous or compound heterozygous mutation. In the same line of reasoning, this genetic cause should be included in the differential diagnosis of young-onset dementia with seizures. Hitherto, adult neuronal ceroid lipofuscinosis (also known as Kufs disease) remains the prototype of this presentation.

The precise molecular and cellular mechanisms underlying the pathogenesis of these diseases are not yet known. There seems to be no correlation between the type of mutation and the associated phenotype because nonsense, splice site, and missense mutations have now been associated with FTD cases. TREM2 is a membrane protein that forms a receptor-signaling complex with TYROBP, triggering the activation of the immune response, differentiation of dendritic cells and osteoclasts, and phagocytosis in microglia. It is interesting to note that a heterozygous variant (p.R47H) in TREM2 has recently been shown to increase the risk for Alzheimer's disease (Guerreiro et al., 2013a; Jonsson et al., 2013). This suggests that TREM2 is part of a functional network involved in different neurodegenerative dementias (FTD, Alzheimer's disease, and Nasu-Hakola), but besides the fact that homozygous mutations cause an early-onset and more severe disease, whereas heterozygous variants increase the risk for a late-onset disorder, it is not possible to establish a specific correlation between genotype and phenotype.

Disclosure statement

The authors have no actual or potential conflicts of interest.

Acknowledgements

This work was supported by the Alzheimer's Research UK, by an anonymous donor, by the Wellcome Trust/MRC Joint Call in Neurodegeneration award (WT089698) to the UK Parkinson's Disease Consortium whose members are from the University College London/Institute of Neurology, the University of Sheffield, and the MRC Protein Phosphorylation Unit at the University of Dundee, and by a fellowship from Alzheimer’s Research UK to Dr Guerreiro. The authors thank Fatih Tepgec and Seda Buker for their help in obtaining the samples and neuropsychological data and the NHLBI GO Exome Sequencing Project and its ongoing studies that produced and provided exome variant calls for comparison: the Lung GO Sequencing Project (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO Sequencing Project (HL-102925), the Seattle GO Sequencing Project (HL-102926), and the Heart GO Sequencing Project (HL-103010).

Footnotes

[star]This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

References

Chouery E., Delague V., Bergougnoux A., Koussa S., Serre J.L., Megarbane A. Mutations in TREM2 lead to pure early-onset dementia without bone cysts. Hum. Mutat. 2008;29:E194–E204. [PubMed]
Giraldo M., Lopera F., Siniard A.L., Corneveaux J.J., Schrauwen I., Carvajal J., Munoz C., Ramirez-Restrepo M., Gaiteri C., Myers A.J., Caselli R.J., Kosik K.S., Reiman E.M., Huentelman M.J. Variants in triggering receptor expressed on myeloid cells 2 are associated with both behavioral variant frontotemporal lobar degeneration and Alzheimer's disease. Neurobiol. Aging. 2013 34, 2077. [PMC free article] [PubMed]
Guerreiro R., Wojtas A., Bras J., Carrasquillo M., Rogaeva E., Majounie E., Cruchaga C., Sassi C., Kauwe J.S., Younkin S., Hazrati L., Collinge J., Pocock J., Lashley T., Williams J., Lambert J.C., Amouyel P., Goate A., Rademakers R., Morgan K., Powell J., St George-Hyslop P., Singleton A., Hardy J. TREM2 variants in Alzheimer's disease. N. Engl. J. Med. 2013;368:117–127. [PubMed]
Guerreiro R.J., Lohmann E., Bras J.M., Gibbs J.R., Rohrer J.D., Gurunlian N., Dursun B., Bilgic B., Hanagasi H., Gurvit H., Emre M., Singleton A., Hardy J. Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement. JAMA Neurol. 2013;70:78–84. [PubMed]
Jonsson T., Stefansson H., Steinberg S., Jonsdottir I., Jonsson P.V., Snaedal J., Bjornsson S., Huttenlocher J., Levey A.I., Lah J.J., Rujescu D., Hampel H., Giegling I., Andreassen O.A., Engedal K., Ulstein I., Djurovic S., Ibrahim-Verbaas C., Hofman A., Ikram M.A., van Duijn C.M., Thorsteinsdottir U., Kong A., Stefansson K. Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 2013;368:107–116. [PubMed]
Klunemann H.H., Ridha B.H., Magy L., Wherrett J.R., Hemelsoet D.M., Keen R.W., De Bleecker J.L., Rossor M.N., Marienhagen J., Klein H.E., Peltonen L., Paloneva J. The genetic causes of basal ganglia calcification, dementia, and bone cysts: DAP12 and TREM2. Neurology. 2005;64:1502–1507. [PubMed]
Kuroda R., Satoh J., Yamamura T., Anezaki T., Terada T., Yamazaki K., Obi T., Mizoguchi K. A novel compound heterozygous mutation in the DAP12 gene in a patient with Nasu-Hakola disease. J. Neurol. Sci. 2007;252:88–91. [PubMed]
Paloneva J., Autti T., Raininko R., Partanen J., Salonen O., Puranen M., Hakola P., Haltia M. CNS manifestations of Nasu-Hakola disease: a frontal dementia with bone cysts. Neurology. 2001;56:1552–1558. [PubMed]